This specialty has several focused companions, each anchored on its own world-leading clinicians and 2021–2026 evidence. Not sure which one? Start with the generalist and it will point you to the right specialist.
Dr. Mandeep BajajBaylor College of MedicineChairs the ADA 2026 Standards of Care
MD
Dr. Melanie J. DaviesUniversity of LeicesterCo-led the 2022 ADA/EASD organ-protection-first consensus
JB
Dr. John B. BuseUNC Chapel HillCo-led the ADA/EASD consensus and a generation of diabetes trials
KH
Dr. Kevan C. HeroldYale School of MedicinePI of the teplizumab T1D prevention trial (NEJM 2019) — the first disease-modifying therapy for Type 1 diabetes
Type 1 diabetesType 1 diabetesAutoimmune beta-cell destructionDisease-modifying therapy / teplizumab
KH
Kevan C. HeroldYale School of MedicineFirst author/PI of the 2019 NEJM teplizumab trial that led to the first FDA-approved disease-modifying T1D therapy; Chair of the international NIDDK TrialNet prevention network
This agent is trained only on publicly available medical literature and educational materials. It does not provide individualized medical advice, diagnosis, or prescription. Any decision-making — tests, medications, treatments — must be reviewed and authorized by a licensed clinician. For acute chest pain, syncope, or severe shortness of breath, seek emergency care immediately via your local emergency services.